Institut Bergonié 1 MULTICENTRIC EVALUATION OF THE FRENCH SURGICAL SYSTEM IN SOFT TISSUE SARCOMA (STS). E. Stoeckle, S. Bonvalot, JY Blay, L. Guillou,

Slides:



Advertisements
Similar presentations
Radiologic Imaging Defines the local extent of a tumor Can be used to stage malignant disease Aids in the diagnosis Monitoring tumor changes after treatment.
Advertisements

Nadya Dimitrova Marieta Petkova. 13 Regional cancer registries BNCR: -Established in 1952; cases a year; million population;
Primary thoracic sarcomas: prognostic factors and outcome in a series of patients treated at a single institution Leonardo Duranti T horacic Surgery.
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Janet Eary 1, Janet O'Sullivan 3, Finbarr O'Sullivan 3, E. U. Conrad 2 1. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States.
Clinicopathologic Characteristics and Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery Emily.
LOCAL CONTROL AMONG YOUNG PATIENTS WITH NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA (NRSTS) FOLLOWING RISK-BASED TREATMENT: RESULTS FROM CHILDREN’S ONCOLOGY.
Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases Takuro Wada, O Sato, A Kawai, T Hasegawa Sapporo.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
A MULTICENTRIC PHASE I STUDY OF SUNITINIB WITH CONCOMITANT RADIATION THERAPY IN INOPERABLE SARCOMAS (GIST EXCLUDED) M.P. SUNYACH, D. PEROL, N. PENEL, P.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
Kerrington Smith, M.D. CTOS Nov 14, 2008
Failure of Treatment in Cervical Cancer Patients *Dr. Zohreh Yousefi fellow ship of gynecology oncology of Mashhad university Fatemeh Homaee, Marzieh.
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
Sphincter preserving surgery after preoperative treatment for ultra-low rectal carcinoma. A French multicenter prospective trial: GRECCAR 1 P Rouanet,
CLINICAL PRACTICE GUIDELINES Connective Tissue Oncology Society 2005 Meeting, Boca Raton Vivien Bramwell Chair, NCIC-CTG Sarcoma Committee Canadian Sarcoma.
12 th Annual CTOS Meeting 2006 POSTER VIEWING OF SESSION 6.
Paris- RP Reims Rennes Tours Marseille Montpellier Lyon Nice Lille Strasbourg Bordeaux Dijon Besançon Nantes Toulouse Poitiers Angers Nancy Caen Rouen.
Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,
An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.
Quantifying the Morbidity of the Unplanned Sarcoma Excision
Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
“Validation” of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients Yang Zhao; Heng Zhao Division of Thoracic.
EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.
Per-Ulf Tunn, D. Andreou, S. Fehlberg, M. Werner, P. Reichardt
Chiba Cancer Center, Chiba, Japan Shintaro Iwata Tsukasa Yonemoto Yoko Hagiwara Takeshi Ishii Division of Orthopedic Surgery Akinobu Araki Dai Ikebe Division.
on behalf of the ACOSOG Z4032 Investigators
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Prognostic value of myogenic differentiation in adult soft tissue sarcomas (STS) A study of 855 cases from the French Sarcoma Group N Stock, MC Chateau,
Jens Jakob 1 ; Anna Simeonova 2 ; Bernd Kasper 3 ; Ulrich Ronellenfitsch 1 ; Frederik Wenz 2 ; Peter Hohenberger 1 1 Department of Surgery, 2 Department.
Aggressive extra-abdominal fibromatosis: can aggressive management be avoided in a subgroup of patients ? S. Bonvalot *, H. Eldweny *, V Haddad A. Le Cesne,
CTOS years Experience of Management of Malignant Phyllodes Tumor and Breast Sarcoma at Princess Margaret Hospital Princess Margaret Hospital &
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
Malignancy Grade and Histologic Subtype of Primary Retroperitoneal Sarcoma (RPS) are Predictive of Pattern of Recurrence: a Large Retrospective Study from.
14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.
The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.
Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.
Poster # 18, abstract # 4530 Long term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous.
French Guidelines (SOR): Any Impact Since 1995? BN Bui Institut Bergonié, Bordeaux FSG CETOS 2005.
Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.
Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,
Local Recurrence Growth Rate Predicts Outcome In Locally Recurrent Retroperitoneal Liposarcoma James Park, MD, Li-Xuan Qin, PhD, Francesco Prete, MD Murray.
Patterns of Care and Prognosis of Retroperitoneal Sarcomas in the Primary and Advanced Settings A Large Multicentric Retrospective Analysis from the French.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.
ACOSOG Sarcoma Committee Chair: Peter W.T. Pisters, MD Vice Chairs: Edward Cheng, MD (Orthopedic Oncology) Robert Maki, MD, PhD (Medical Oncology) Brian.
Multifocal myxoid liposarcoma, metastasis or second primary tumor
IMRT delivery of preoperative, high dose radiotherapy to a large volume, with Simultaneous Integrated Boost (SIB) in retroperitoneal sarcomas: The Ottawa.
Prognosis of younger patients in non-small cell lung cancer
The Scandinavian Sarcoma Group 25 Years´Jubilee Meeting St
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
French Sarcoma Group CTOS meeting, Nov 2004
Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung
Sarcoma Wound Complications
PRIMARY EXTREMITY STS: MULTIMODAL APPROACH MAY HAVE IMPROVED SURVIVAL
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
HISTOLOGY-SPECIFIC NOMOGRAM FOR PATIENTS AFFECTED BY PRIMARY RSTS
Surgical resection of metachronous liver metastases
Presentation transcript:

Institut Bergonié 1 MULTICENTRIC EVALUATION OF THE FRENCH SURGICAL SYSTEM IN SOFT TISSUE SARCOMA (STS). E. Stoeckle, S. Bonvalot, JY Blay, L. Guillou, J. Fraisse, JL. Verhaeghe, JM. Coindre, BN Bui From the French Sarcoma Group

Institut Bergonié 2 Why another classification?  Surgery is no more the only treatment for STS:  Formerly, subjectivity of surgeon-based definitions of quality of surgery had no impact on treatment modalities: wait and see  Actually, multimodality treatment needs to know: - who will recur - to whom give additional treatment and how  Furthermore, homogenous treatment reporting is needed  However, quality of surgery remains subjective:  Surgeon – dependentor  Pathologist - dependent

Institut Bergonié 3 The UICC classification  The UICC recommends the R - classification in STS:  R0:resection in sano  R1:microscopic residual disease  R2: macroscopic residual disease  But it does not give instructions how to determine R!  Usually, Enneking’s classification is transposed into the R - classification

Institut Bergonié 4 Individual appreciation of quality of surgery is not appropriate!  Surgeons overestimate excision  Almost large  German registry (Junginger 2001):  Extremity sarcoma82% R0  Retroperitoneal sarcoma64% R0  Local recurrences remain elevated  Pathologists underestimate excision  Retraction of tissue  Negative specimen after re-excision in 50%

Institut Bergonié 5 The FSG system (I) : OP reports review in 8 participating centers: missing information : multicentric feasibility study of items for OP reporting:  Only describe  Important issues:tumor seen? tumor rupture? : Recommendations for pathology reporting (Ghnassia). 4.Determination of resection type (UICC R system) by surgeon and pathologist.

Institut Bergonié 6 The FSG system (II) : prospective validation in a single center (Bordeaux): 109 consecutive patients with trunk wall + extremity, conservative surgery, 68% R0, 56 months FU: 3% R0 Local recurrence:8%( P < 0,01) 19% R1 Negative predictive value of R0: 97% 5. Actual study: multicentric evaluation

Institut Bergonié 7 Methods  Methods:  FSG data base - multivariate prognostic factor analysis  Patients’ selection:  resection type (R) informed: 423 pts. 325 pts. with trunk wall or extremity STS 302 pts. N0 M0  Inclusion and follow-up:  , FU: 21 months (1 – 104 months)  Accrual by center: Bordeaux88 Villejuif52 Lyon52 Lausanne24 Nancy22 0ther centers64

Institut Bergonié 8 Patients’ characteristics  M/F:150/152 pts.  Localizations:  Shoulder girdle 12 4%  Upper extremity 3612%  Trunk wall 3110%  Pelvic girdle 24 8%  Lower extremity19966%

Institut Bergonié 9 Tumor extension  Superficial tumors: 56 pts. (18,5%)  Median size: 9 cm (1 – 26 cm)  Multifocality: 31 pts. (10,3%)  Vasc./nerve involvement: 47 pts. (15,6%)  AJC/UICC stage 1979:  I: 14% II: 28% III: 33% IV: 15% NP: 10%  AJC/UICC stage 2002:  IA: 15% IB: 35% IIA: 13% IIB: 2% III: 29% NP: 5%

Institut Bergonié 10 Pathology  Histological subtypes:  Liposarcoma70 (23%)  Leiomyosarcoma46 (15%)  MFH44 (15%)  Synovialosarcoma25 (8%)  MPNST + RhabdoS.15 (5%)  Unclassified S.39 (13%)  Others + NP63 (21%)  Grade I: 17% II: 34% III: 45% NP: 5%

Institut Bergonié 11 Treatments  302 operated patients:  First-line surgery:83%  Resection types : R0220 (73%) R1 68 (22%) R2 14 (5%)  Radiotherapy:62%  Chemotherapy:40%

Institut Bergonié 12 Treatment results R0 213  CR:272 (90%) R1 54 R2 5  Survivors:240 (80%) actuarial 65%  LR:crude 34 (13%) actuarial 21%

Institut Bergonié 13 Overall survival TSURV Survie cumulée 1,0,9,8,7,6,5,4,3,2,1 0,0

Institut Bergonié 14 Resection-type according to center (NS) CenterNR0 Bordeaux8873% Villejuif5273% Lyon5264% Lausanne2483% Nancy2264% Others6480%

Institut Bergonié 15 Resection type according to localization (NS) Localization NR0 Shoulder girdle 1275% Upper extremity 3656% Trunk wall 3171% Pelvic girdle 2467% Lower extremity19977%

Institut Bergonié 16 Local recurrence-free interval TRLOC Survie cumulée 1,0,9,8,7,6,5,4,3,2,1 0,0

Institut Bergonié 17 Local recurrence according to R P = 0,004 R0 R1 + R2

Institut Bergonié 18 Local recurrence according to grade P = 0,019 Grade Grade 3

Institut Bergonié 19 Local recurrence according to T3 (1979 UICC classification) P = 0,049 T1 + T2 T3

Institut Bergonié 20 Local recurrence according to stage AJC/UICC 1979 P = 0,0045

Institut Bergonié 21 Local recurrence according to stage AJC/UICC 2002 P = 0,042

Institut Bergonié 22 Prognostic factors/LR VariableRL Np R R ,004 R1+R Grade , T T1 +T ,05 T Histotype, Size (+/- 5 cm), Localization, Depth, Center, Radiotherapy:NS

Institut Bergonié 23 Independent prognostic factors for local recurrence VariablespRRCI No R00,0033,061,47 - 6,38 Grade 30,0043,351,48 - 7,55

Institut Bergonié 24 Conclusion  Resection type (R) as defined by FSG predicts independently local recurrence  FSG criteria are reproducible and can be used in a multicentric setting  Treatment results in the multicenter study are lower than in the single center: progress still needed.